Fjarde AP Fonden Fourth Swedish National Pension Fund Has $7.36 Million Position in Alexion Pharmaceuticals, Inc. (ALXN)

Fjarde AP Fonden Fourth Swedish National Pension Fund increased its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 2.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 52,471 shares of the biopharmaceutical company’s stock after buying an additional 1,039 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Alexion Pharmaceuticals were worth $7,361,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Fiduciary Trust Co. bought a new stake in Alexion Pharmaceuticals in the second quarter valued at $111,000. Huntington National Bank boosted its holdings in Alexion Pharmaceuticals by 1,084.6% in the second quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock valued at $131,000 after acquiring an additional 987 shares in the last quarter. Penserra Capital Management LLC boosted its holdings in Alexion Pharmaceuticals by 13.0% in the second quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after acquiring an additional 144 shares in the last quarter. Dupont Capital Management Corp bought a new stake in Alexion Pharmaceuticals in the third quarter valued at $156,000. Finally, Acadian Asset Management LLC bought a new stake in Alexion Pharmaceuticals in the second quarter valued at $160,000. 96.71% of the stock is currently owned by institutional investors.

Alexion Pharmaceuticals, Inc. (ALXN) traded down $1.35 during midday trading on Thursday, hitting $108.99. 501,631 shares of the stock traded hands, compared to its average volume of 2,294,207. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $149.34. The stock has a market cap of $24,570.59, a price-to-earnings ratio of 22.49, a P/E/G ratio of 1.20 and a beta of 1.22. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The firm had revenue of $859.00 million during the quarter, compared to analyst estimates of $864.34 million. During the same quarter in the prior year, the firm earned $1.23 EPS. The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. analysts forecast that Alexion Pharmaceuticals, Inc. will post 4.81 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Fjarde AP Fonden Fourth Swedish National Pension Fund Has $7.36 Million Position in Alexion Pharmaceuticals, Inc. (ALXN)” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://sportsperspectives.com/2017/11/16/fjarde-ap-fonden-fourth-swedish-national-pension-fund-has-7-36-million-position-in-alexion-pharmaceuticals-inc-alxn.html.

In other news, EVP Julie O’neill sold 11,160 shares of the company’s stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $140.00, for a total transaction of $1,562,400.00. Following the completion of the sale, the executive vice president now owns 26,704 shares of the company’s stock, valued at approximately $3,738,560. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ann M. Veneman sold 835 shares of the company’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total transaction of $121,751.35. Following the sale, the director now directly owns 5,480 shares of the company’s stock, valued at approximately $799,038.80. The disclosure for this sale can be found here. Insiders have sold a total of 16,490 shares of company stock valued at $2,337,251 in the last ninety days. Insiders own 4.35% of the company’s stock.

Several analysts recently weighed in on the stock. BidaskClub cut shares of Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, August 14th. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $158.00 target price on the stock in a report on Wednesday, August 2nd. Leerink Swann restated a “buy” rating and set a $182.00 target price on shares of Alexion Pharmaceuticals in a report on Monday, September 25th. BMO Capital Markets restated an “outperform” rating and set a $173.00 target price (up previously from $168.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. Finally, Evercore ISI initiated coverage on shares of Alexion Pharmaceuticals in a report on Wednesday, August 16th. They set an “in-line” rating and a $137.00 target price on the stock. Six analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $154.01.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply